I am a mathematical statistician. Through more than 20 years in various biostatistical roles I have complemented my thorough theoretical background with expertise in biostatistics. I am passionate about applying this expertise to solve problems in pharmaceutical drug development.
I am an Accredited European Statistician, a qualification issued by The Federation of European National Statistical Societies.
CV Publications Talks Teaching
Postdoc in Mathematical Statistics, 2007
Stanford University, United States
PhD in Mathematics, 2006
University of Bern, Switzerland
MSc in Mathematical Statistics and Actuarial Science, 2001
University of Bern, Switzerland
Together with two colleagues I have written an introductory Medical Statistics textbook.
A considerable amount of software grew out of my research. Most of this code is made available as packages for the freely available software R and can be downloaded from CRAN.
Alexandra Erdmann and Kaspar Rufibach (2023): simIDM: Simulating Clinical Trials with Endpoints Progression-Free Survival and Overall Survival using an Illness-Death Model
Kaspar Rufibach, Lynda Grinsted, Jiang Li, Hans-Jochen Weber, Cheng Zheng, Jiangxiu Zhou (2023+): Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions
Kaspar Rufibach (2021): eventTrack: Event Prediction for Time-to-Event Endpoints
Regina Stegherr and Kaspar Rufibach (2020). SAVVY: estimation of AE probabilities.
Björn Bornkamp, Kaspar Rufibach, Jianchang Lin, Yi Liu, Devan Mehrotra, Satrajit Roychoudhury, Heinz Schmidli, Yue Shentu, Marcel Wolbers (2020): Principal Stratum Strategy: Potential Role in Drug Development
Kaspar Rufibach, Dominik Heinzmann, Annabelle Monnet (2019): Integrating Phase 2 into Phase 3 based on an Intermediate Endpoint While Accounting for a Cure Proportion - with an Application to the Design of a Clinical Trial in Acute Myeloid Leukemia
Elina Asikanius, Kaspar Rufibach, Jasmin Bahlo, Gabriele Bieska, Hans Ulrich Burger (2016). Comparison of design strategies for a three-arm clinical trial with time-to-event endpoint: power, time-to-analysis, and operational aspects. Biom. J., 58(6), 1295-1310.
Kaspar Rufibach, Paul Jordan, Markus Abt (2016): bpp: Computations Around Bayesian Predictive Power
Stanislas Hubeaux and Kaspar Rufibach (2014): SurvRegCensCov: Weibull Regression for a Right-Censored Endpoint with Interval-Censored Covariate
Dominic Schuhmacher, Kaspar Rufibach, and Lutz Duembgen (2011): logconcens: Maximum likelihood estimation of a log-concave density based on censored data
Kaspar Rufibach, Fadoua Balabdaoui, Hanna Jankowski, and Kathrin Weyermann (2011): logcondiscr: Estimate a Log-Concave Probability Mass Function from Discrete i.i.d. Observations
Leonhard Held and Kaspar Rufibach, with further contributions by others (2010): biostatUZH: Misc Tools of the Department of Biostatistics, EBPI, University of Zurich
Kaspar Rufibach (2010): selectMeta: Estimation of Weight Functions in Meta Analysis
Kaspar Rufibach (2009): OrdFacReg: Least Squares, Logistic, and Cox-Regression with Ordered Predictors
Fadoua Balabdaoui, Kaspar Rufibach, Filippo Santambrogio (2009): OrdMonReg: Compute least squares estimates of one bounded or two ordered isotonic regression curves
Rufibach, K (2008): reporttools: Generate LaTeX Tables of Descriptive Statistics
Kaspar Rufibach and Guenther Walther (2007): modehunt: Multiscale Analysis for Density Functions
Kaspar Rufibach and Samuel Mueller (2006): smoothtail: Smooth Estimation of GPD Shape Parameter
Kaspar Rufibach and Lutz Duembgen (2006): Estimate a Log-Concave Probability Density from i.i.d. Observations
I am regularly teaching to statisticians and non-statisticians about various biostatistical topics. Slides are available for download for some of the courses.
At Roche, I am responsible for the technical training planning of about 200 biostatistics staff. I coordinate a major chunk of the biostatistics courses for non-statistics functions. A full-day introductory biostatistics course that I have given together with Marcel Wolbers has been selected as part of the official training program for all Roche affiliates globally.
*Kaspar Rufibach (Roche), Gernot Wassmer (rpact), Marc Vandemeulebroecke (Novartis), Marcel Wolbers (Roche)
Mouna Akacha, Robin Dunn, Tianmeng Lyu (all Novartis), Shanti Gomatam (FDA), Kaspar Rufibach (Roche)
Within first Effective Statistician conference.
Within MSc program Master of Pharmaceutical Sciences in Drug Development and Regulatory Affairs, University of Innsbruck, Austria.
Kaspar Rufibach and Marcel Wolbers (Roche)
Mar Vazquez Rabunal, 4-month full-time internship within Department of Biostatistics, Roche Basel. Co-supervised with Marcel Wolbers and Daniel Sabanes Bove (Roche Basel).
Amit Sawant, 4-month full-time internship within Department of Biostatistics, Roche Basel
Kaspar Rufibach
Marc Vandemeulebroecke, Kaspar Rufibach, Gernot Wassmer, and Marcel Wolbers, course on behalf of the BBS
Claude Berge, Frank Dahlke, and Kaspar Rufibach, Roche-internal course
Kaspar Rufibach and Marcel Wolbers, Roche-internal course
Kaspar Rufibach, shortcourse given in collaboration with DIA
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, shortcourse given for all Roche biostatisticians
Kaspar Rufibach, course for clinical reviewers at ANVISA (Brazilian Health Authority)
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach and Godwin Yung, shortcourse given for all Roche biostatisticians
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach and Evgeny Degtyarev, shortcourse given at 76th Annual Deming Conference on Applied Statistics
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach and Marcel Wolbers, Roche-internal course
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Zurich University Hospital
Kaspar Rufibach
Xijin Chen, 3-month full-time internship within Department of Biostatistics, Roche Basel
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Roche-internal course
Marc Vandemeulebroecke, Kaspar Rufibach, Gernot Wassmer, and Marcel Wolbers, course on behalf of the German Region of the IBS
Kaspar Rufibach and Marcel Wolbers, pre-conference course at ISCB 40, Leuven
Kaspar Rufibach and Marcel Wolbers, Roche-internal course
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Baden Hospital
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Roche-internal course
Marc Vandemeulebroecke, Kaspar Rufibach, Daniel Sabanes-Bove, and Marcel Wolbers, course on behalf of the BBS
Kaspar Rufibach, Baden Hospital
Kaspar Rufibach, Roche-internal course
Ke Li, master thesis to obtain MSc in biostatistics, Department of Biostatistics, University of Zurich
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach and Marcel Wolbers, Roche-internal course
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, courses for medical doctors at five hospitals
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Certificate of Advanced Studies (CAS) course, as part of the Master of Advanced Studies in Managed Health Care
Matthias Meller, master thesis to obtain MSc in biostatistics, University of Ulm
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, Certificate of Advanced Studies (CAS) course, as part of the Master of Advanced Studies in Managed Health Care
Kaspar Rufibach, courses for medical doctors at four hospitals
Kaspar Rufibach, Certificate of Advanced Studies (CAS) course, as part of the Master of Advanced Studies in Managed Health Care
Monika Hebeisen, thesis to obtain MSc in biostatistics, Department of Biostatistics, University of Zurich
Kaspar Rufibach, within MSc biostatistics program at University of Zurich
Kaspar Rufibach, full-day course for Roche biostatisticians
Stanislas Hubeaux, 6-month full-time internship within Department of Biostatistics, Roche Basel
Kaspar Rufibach, Roche-internal course
Kaspar Rufibach, courses for medical doctors at seven hospitals
Philipp Boutellier, master thesis to obtain MSc in medicine, University of Zurich
Kaspar Rufibach, within MSc biostatistics program at University of Zurich
Kaspar Rufibach, Certificate of Advanced Studies (CAS) course, as part of the Master of Advanced Studies in Managed Health Care
Dominik Loiero, master thesis to obtain MSc in medicine, University of Zurich
Kaspar Rufibach and Eva Furrer, within MSc biostatistics program at University of Zurich
Kaspar Rufibach, cancer biology PhD program, University of Zurich
Kaspar Rufibach, course for medical students, Zurich University hospital
Leonhard Held and Kaspar Rufibach, University of Mainz, Germany
Kaspar Rufibach, continuing education for radiologists, Bern University Hospital
Almut Scherer, Semester thesis, Department of Biostatistics, University of Zurich
Leonhard Held and Kaspar Rufibach, MSc of Medical Biometry program, University of Heidelberg
Leonhard Held and Kaspar Rufibach, within MSc biostatistics program at University of Zurich
Kaspar Rufibach, within MSc biostatistics program at University of Zurich
Leonhard Held and Kaspar Rufibach, within MSc biostatistics program at University of Zurich
Rita Achermann, Semester thesis, Department of Biostatistics, University of Zurich
Kaspar Rufibach, within MSc sport science program at University of Bern
Kaspar Rufibach, continuing studies, University of Bern
Karin Lanz and Marco Weber, Swiss Technical School for Optometrics, Olten, Switzerland
I am a member of several cross-industry working groups. Further information on these is provided below.
Here I collect links to posts I wrote on various topics, mainly on linkedin.
02.04.2023: Why do we do interim analyses clinical trials?
29.03.2023: Quantification of follow-up
07.03.2023: How can the estimands addendum framework be “married” with competing risks?
02.02.2023: Trial design using multistate modelling for PFS and OS
04.01.2023: Estimation of AE risk in RCTs
02.12.2022: Are regulators on board with estimands?
01.05.2022: Thoughts on my 10th year anniversary at Roche